Johnson & Johnson Announces TREMFYA Long‑Term Data Show Sustained Clinical And Endoscopic Remission In Ulcerative Colitis Through 3 Years
Johnson & Johnson reported new long‑term results from the QUASAR extension study showing that TREMFYA maintained high rates of clinical and endoscopic remission through Week 140 (about 3 years) in adults with moderately to severely active ulcerative colitis, with over 80 % of patients in clinical remission and more than half achieving endoscopic remission. The data, presented at the European Crohn’s and Colitis Organisation 2026 conference, also showed sustained intestinal healing without new safety concerns, reinforcing confidence in the long‑term use of guselkumab for durable disease control. 
Johnson & Johnson Announces TREMFYA Long‑Term Data Show Sustained Clinical And Endoscopic Remission In Ulcerative Colitis Through 3 Years